Andere talen Fusen Pharmaceutical Company Limited

Aandelen

1652

KYG370981030

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:09:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,88 ^HKD	-1,12%		-2,22%	-35,77%

04/04	Fusen Pharmaceutical's medicijnaanvraag voor type 2 diabetes aanvaard door Chinese regelgevende instantie	MT
03/04	Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited kondigt aan dat de National Medical Products Administration van de Volksrepubliek China de aanvraag voor de lancering van Metformine Empagliflozin Tabletten (I) accepteert	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator	04/04
Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)	03/04
Fusen Pharmaceutical Posts Higher Loss in 2023	01/04
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	15/03
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	29-08-23
Fusen Pharmaceutical Forecasts Return to Profitability in H1	11-08-23
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023	10-08-23
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 75,843,900 shares, representing 10% of its issued share capital, under the authorization approved on May 30, 2023.	31-05-23
Fusen Pharmaceutical Company Limited's Equity Buyback announced on June 2, 2022, has expired.	30-05-23
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	28-03-23
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	28-03-23
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Year Ended 31 December 2022	28-03-23
Fusen Pharmaceutical to Swing to Loss in 2022	14-03-23
Fusen Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ended 31 December 2022	13-03-23
Fusen Pharmaceutical, Directors Hit with Disciplinary Action for Disclosure Breaches	04-01-23
Fusen Pharmaceutical Company Limited Announces Change of Principal Place of Business in Hong Kong	15-12-22
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	29-08-22
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29-08-22
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022	29-08-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Fusen Pharmaceutical Company Limited

Aandelen

1652

KYG370981030

Andere talen

Filters